


The invention relates to the chemistry of natural compounds and medicinal chemistry, in particular to an *ent*-kaurenoic acid derivative containing an azide functional group, which exhibits selective cytotoxic properties in relation to human cancer cells and can be used as a chemotherapeutic agent for the treatment of oncological diseases.

According to the invention, claimed is the methyl *ent*-15-hydroxy-16-azido-17-carboxy-methoxymethylkauranoate compound of the formula:



The claimed compound possesses selective cytotoxic activity against the Capan-1 (pancreatic adenocarcinoma), NCI-H460 (lung carcinoma) and DND-41 (acute lymphoblastic leukemia) tumor cell lines at micromolar and submicromolar concentrations.

Claims: 2

Fig.: 3